























 What is already known about this topic?  
Atopic dermatitis (AD) has been found to affect quality of life (QOL) in adults with, studies reporting a 
greater impact on QoL with increased severity of AD.  Adults with AD also report poorer QoL 
compared to a healthy population and those with other medical skin conditions such as urticaria and 
psoriasis. 
 
 What does this study add? 
This paper provides the first systematic literature review and meta-analysis of the impact of AD on 
QoL in adults.  Across studies, increased disease severity significantly related to poorer QoL. 
Compared to healthy controls, adults with AD demonstrated significantly lower QoL but findings were 
mixed in studies that compared QoL in AD to other chronic conditions.  Research exploring gender 






















Background: Atopic dermatitis (AD) can affect quality of life (QoL) of adult patients, in whom the 
condition can be severe and persistent. There are currently no systematic reviews of the impact of AD 
on adults. 
Objective: This paper provides the first systematic literature review and meta-analysis of the impact of 
AD on QoL in adults. 
Methods: A systematic search was conducted using MEDLINE, Scopus, and Web of Science for 
articles published until October 2018. Inclusion criteria were a clinical diagnosis of AD, adult patients 
and QoL as an outcome measure.  Interventions were excluded. 
Results: A total of 32 studies were included. While QoL was assessed using Dermatology Life Quality 
Index (DLQI) in 25 studies, there was heterogeneity in the tools used to measure disease severity 
across studies. Meta-analysis of the seven studies that used the SCORAD to measure disease 
severity showed severity to be significantly related to poorer QoL. The remaining 18 studies also 
found increased disease severity significantly related to poorer QoL. When compared to healthy 
controls, AD patients demonstrated significantly lower QoL but findings were mixed in studies that 
compared QoL in AD to other skin conditions.  
Conclusions: The findings highlight the significant impact that AD has on QoL in adults and the need 
for validated and relevant QoL measures to be implemented in clinical assessments for AD. Areas 
that require further research include an exploration of gender differences in QoL and the use of 





Atopic dermatitis (AD) is a chronic debilitating inflammatory skin condition which mainly affects 
children but can also be present in adulthood1. AD is a significant health issue globally, with 
prevalence in children of 15-30% and 2-10% in adults2. The prevalence of AD in developed countries 
has increased two-to threefold over the past thirty years3. AD is characterised by symptoms such as 
itchy, red, dry and inflamed skin. It is a chronic condition in most people, and despite there being no 
cure for the condition, it can be managed well using emollients, topical corticosteroids and oral 
treatments such as antihistamines and immunosuppressant tablets. In the UK, 10-20% of all referrals 
to dermatologists and 30% of dermatology consultations are for AD4. A community study conducted in 
Scotland estimated that 38% of AD cases comprised adults over 16 years old5. Thus, although a 
relatively small percentage patients with AD are adults, studies also indicate a large 
percentage of adults seek treatment when compared to other age groups with AD.5,6.  
 
AD has been shown to have an impact on quality of life in children and adults7-9.  Quality of Life (QoL) 
is defined by the World Health Organization Quality of Life (WHOQoL) Group10 as an “individuals’ 
perceptions of their position in life in the context of the culture and value systems in which they live 
and in relation to their goals, expectations, standards and concerns” (p. 5). Health related QoL 
(HRQoL) is considered a valid indicator when monitoring health and service needs of patients11. 
Measuring HRQoL can help inform interventions to alleviate health conditions and is of potential value 
in performing risk-benefit analyses of clinical decisions for treatment, especially where systemic 
therapy with possible side effects is prescribed.  A review of the literature by Lifshitz7, which focused 
on the impact of AD on QoL primarily of infants, children, adolescents, and their families, reported that 
AD had a significant and lasting effect on HRQoL, in particular on psychological wellbeing and social 
functioning. A review by Lewis-Jones8 on QoL and childhood AD confirmed that QoL in children and 
adolescents was severely impaired with issues such as embarrassment and bullying affecting children 
psycho-socially and physically.  
 
Relatively little research has been conducted with adults who have AD, but the research that has 
been conducted suggests that all aspects of HRQoL are affected in adults with AD, and that HRQoL 
is more compromised in adults with AD when compared to adults with chronic urticaria and psoriasis9.  
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In addition, little is known about how HRQoL of AD patients varies with disease severity; the literature 
that has investigated this issue has found that greater disease severity is related to poorer 
HRQoL12,13. To draw together what is currently known in this area and identify gaps in knowledge, the 
present study reports the results of a systematic review and meta-analysis of the impact of Atopic 
Dermatitis on QoL in adult patients. 
 
METHODS 
Study searches were conducted using three electronic databases: MEDLINE, Scopus and Web of 
Science Core Collection. Databases were searched up to 24th October 2018 with no limit to the start 
date.  Search terms can be found in the supplementary information.  The initial search was conducted 
by the lead author; all members of the study team reviewed all full papers retrieved for evaluation. 
Inclusion/exclusion strategy and data extraction  
To be included in this review studies had to report data from adults. The legal age of adulthood differs 
according to country. This review included participants aged 18 and above or 16 and above if defined 
as an adult in a study, adolescents were excluded. Studies that combined adult and children data into 
one analysis were excluded. Studies that collected data from both adults and children, but reported 
data separately for these sub-groups, were retained in the review. Studies that measured QoL as a 
result of medical or psychological interventions were excluded. Study search was limited to English-
language articles on human populations. Case-reports and conference abstracts were excluded. All 
study types were included if they reported on a QoL measure.   
Outcomes 
The primary outcome in this review was QoL in adult patients with AD. QoL was measured either on 
its own, in relation to disease severity, compared to healthy controls or compared to patients with 
other conditions, such as psoriasis.  
Quality Appraisal  
The quality of the included studies was assessed using the Mixed Methods Assessment Tool 






Data synthesis   
Where studies reported QoL scores using the same instruments, results were pooled using meta-
analysis. In cases where pooling was not considered appropriate, detailed descriptions of study 
characteristics and results were reported alongside study quality.  
 
RESULTS 
Figure 1 outlines the search strategy following the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) standards15.  A total of 32 papers met inclusion criteria and were 
included in this systematic review. No mixed methods or qualitative papers included a measure of 
QoL, therefore all included papers in this review are quantitative and reviewed using narrative 
synthesis. Seven papers reported a correlation between the Dermatology Life Quality Index (DLQI) 
and a validated measure of AD severity (SCORAD). Correlations from these papers were pooled 
using random-effects meta-analysis in Comprehensive Meta-Analysis Version 3 (2005, Biostat Inc.). 
Table 1 reports study characteristics. Using the MMAT, 24 studies were of higher quality, scoring 75-
100% and eight studies were of lower quality, scoring 25-50% (see supplementary Table 1). 
 
Quality of Life 
The DLQI was used to measure QoL in 25 out of 32 studies included in this review. Mean overall 
DLQI scores ranged across studies from 4.9 (small effect on patient’s QoL) to 20.5 (very large effect 
on patient’s QoL). In studies which looked at differences across the dimensions of QoL, the areas that 
were most affected as measured using the DLQI were symptoms and feelings surrounding AD; 
patients felt embarrassed or self-conscious due to their AD and symptoms such as itchy, sore, painful 
and stinging skin had a detrimental impact on their QoL16-21. Personal relationships were the least 
affected dimension of QoL16,17,19,20. Mozaffari et al22 found that patients perceived dressing, 
undressing and bath-time as being most problematic while the dimension ‘family activities’ was least 
affected. Holm et al21 also found that dressing was particularly problematic. Using the EQ-5D as a 
measure of QoL, daily activity and pain/discomfort parameters were reported to be most affected in 





Quality of Life and Disease Severity 
Twenty studies explored the relationship between disease severity and QoL. Nineteen studies looked 
at this using DLQI in AD patients (see Table 2). Eighteen of these reported significant correlations 
between disease severity and DLQI; the more severe the disease, the lower the QoL.  In seven of 
these studies, QoL using the DLQI was compared with disease severity measured using the 
SCORAD 12,16,26,27,28,29,30. These studies were pooled together using random effects meta-analysis 
(See Figure 2).  The sample-weighted average correlation between HRQoL and disease severity was 
r+ = .44 (CI 0.27; 0.59), indicating a medium-sized relationship31, with greater disease severity relating 
to poorer QoL. There was significant heterogeneity in the results (χ2 = 13.78, p < .05). This could 
partly be explained by the small correlation reported by Haeck et al12.. 
 
Two studies25,32 used the EASI to measure AD severity in relation to QoL.  Both studies found 
statistically significant relationships between QoL and disease severity (ps < .05); QoL was perceived 
as being poorer with increasing disease severity, with personal relationships being related to a lesser 
extent to disease severity than other domains. . 
 
Nine studies13,17,18,19,22,23,24,34,35 explored relationships between patient-assessed disease severity and 
DLQI scores and reported statistically significant medium to large sized correlations whereby an 
increase in disease severity was associated with a decrease in QoL.. Two studies37,38 explored 
gender differences and found a significant positive correlation between patient-assessed disease 
severity and DLQI score (p < .001) and between visible regions and DLQI score (p = .001) for women, 
however neither of these correlations were observed in men.  
 
Two studies33,39 assessed severity using the Rajka & Langeland scoring system which measures 
clinical course, severity, and extent of AD. Both studies found statistically significant correlations 
between disease severity and QoL. Highest correlations found were between disease severity and 
symptoms and feelings; higher disease severity was related to worsening symptoms and feelings as a 




Ten studies used the SF-36 to measure QoL; six of these looked at the relationship between SF-36 
scores and disease severity17,19,24,25,32,33,40,41 . Five studies found significant correlations between 
disease severity and the SF-36, with increased severity associated with poorer QoL. However one 
study25 found no significant correlations between any SF-36 subscales and clinically measured 
disease severity (EASI). The correlations between the SF-36 and disease severity across the six 
studies were small to large-sized. The mean physical dimension scores appeared to be less impaired 
in AD patients compared to the mean mental component scores of the scale17,24,32,3342,43  .  
 
Quality of life in patients with AD compared to healthy controls or other patient groups 
A total of 15 studies compared adults with AD QoL to that of healthy controls.  Ten studies used 
generic QoL scales such as the SF-36 to enable comparison across groups19,23,24,25,33,35,40,41,43,44 ., 
three studies used dermatology specific QoL scales to make comparisons22,26,45 and three 
studies35,37,46 used both generic and dermatology specific scales.  Overall QoL was significantly 
poorer in those with AD compared to healthy controls and, domains such as mental health and social 
functioning were affected to a greater extent in AD patients17,22,29,35 . In a recent study by Misery et al46 
scores on the mental dimension of the SF-12 were lower in AD patients with visible area involvement 
compared to those without (p<0.001).  
 
Two studies compared QoL between vitiligo and AD patients34,45 and found significantly lower QoL in 
the AD groups compared to the vitiligo groups (ps<0.001). Four studies compared QoL between 
psoriasis and AD patients9,19,34,41. Two of these studies found that AD patients had significantly lower 
QoL than patients with psoriasis9,34 whereas Lunderberg et al.19 found significant differences in the 
physical and mental functioning domains; with AD patients scored better than patients with psoriasis. 
Eckert et al41 found no significant differences in QoL ratings in patients with psoriasis or AD. Grob et 
al9 also compared AD with chronic urticaria and found that AD patients were more affected by skin 
discomfort than chronic urticaria patients.  They also had lower scores in relation to ‘treatment 







This systematic review examined the impact of AD on QoL in adults. The DLQI and the SF36 were 
the most frequently used scales to measure QoL in patients with AD, and studies in this review looked 
at QoL in relation to disease severity, other chronic skin conditions, or healthy controls. The 
qualitative synthesis of results and meta-analysis show that there is a consistent relationship between 
increasing AD severity and poorer QoL in adults, and adult patients with AD have poorer QoL than 
healthy groups.  Findings are more equivocal for comparisons with other chronic skin conditions. 
 
Qol and disease severity 
Nineteen of the 20 studies that measured QoL in relation to disease severity found increased disease 
severity was significantly related to poorer QoL. This finding is consistent with reviews looking at QoL 
in children with AD8,47. Almost all adult patients had mild to moderate AD in the studies included in this 
review. Interestingly, in paediatric studies where more patients had moderate to severe AD, QoL 
correlated less well with disease severity than the adult patients with mild to moderate AD in this 
review48,49. The consistent finding that disease severity was related to QoL underscores not only the 
importance of offering both dermatological and psychological treatment to patients, but also the need 
to incorporate QoL screening tools in dermatology. Nonetheless, AD is a complex condition and QoL 
cannot solely be explained by severity of the disease as most studies reported low to medium 
correlations between the two variables. One factor that may influence QoL and may explain 
differences between studies is time of recruitment whereby patients could be experiencing a flare-up 
during recruitment, thus affecting QoL scores; this is especially the case if participants were recruited 
during dermatology visits.  
 
QOL and patients with AD compared to other healthy controls 
All studies that compared QoL in AD patients to healthy controls found significantly lower QoL in AD 
patients. However, four studies used the DLQI measure to explore this difference; the DLQI is a 
dermatology specific questionnaire with questions that are not suitable for use in a sample of the 
general population. In such cases, generic QoL measures such as the SF-36 should be employed. 
When using the SF-36, better physical QoL was reported by studies in this review compared to 
mental QoL. This is in line with a systematic review carried out looking at QoL in psoriasis patients50. 
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The SF-36 is probably not sensitive enough to measure the physical limitations of AD due to its 
generic nature; questions relating to walking abilities for example are unlikely to be relevant to this 
group.   
 
QOL and patients with AD compared to other chronic skin conditions 
Studies comparing QoL to other chronic skin conditions had mixed results, but for those comparing 
vitiligo and AD patients, significantly lower QoL was seen for AD. This may be because vitiligo is not 
accompanied by symptoms such as itching, inflammation, and sleeplessness. Symptoms such as 
pruritus have more of an impact on QoL than visual aspects; indeed, this review found that the area of 
QoL most affected was symptoms surrounding AD. Studies reporting better physical and mental 
functioning scores in patients with AD compared to those with psoriasis and poorer scores in patients 
with AD regarding skin discomfort compared to urticaria suggests that pruritus is the dominant factor 
that interferes with everyday life. Further, the contrast between lower scores related to ‘treatment 
induced restrictions’ in patients with AD and better scores in patients with chronic urticaria suggest 
that topical treatments can be highly restrictive to patients. Indeed, alternative/complementary 
therapies for AD, such as Chinese herbal therapy have become increasingly popular51,52,53 
 
Demographic characteristics of patients 
Many of the participants in the included studies were female.  Partly this reflects health care 
utilization, whereby women use more health services and an estimated 67% of women worldwide 
make all medical choices in society54; in this case, most of the participants were out-patients in 
dermatology clinics. Only one study looking primarily at gender differences in QoL and AD and found 
no significant correlation between disease severity and QoL in males but a significant positive 
correlation was present in females. Thus, the extent to which the AD severity is correlated with QoL in 
in relation to females rather than males deserves further research attention. Lesions located in visible 
areas have been found to affect women more than men37 possibly because women may have a 
higher ideal of culturally determined physical appearance than men so more attention is given to the 
skin.  Gender differences have been found in other allergic conditions with females presenting more 






Limitations of the studies in this review 
The heterogeneity in tools used to measure disease severity made it impossible to pool results across 
all included studies. The SCORAD and EASI are generally preferred by researchers over patient-
assessed severity or visual analogue scales as they are validated measures of disease severity. 
However, they do not cover all issues affected in AD patients, for example, SCORAD only measures 
disease severity over the preceding three days, therefore long-term severity effects on QoL cannot be 
inferred. Nevertheless, studies that included both patient-assessed severity and objective measures 
found relatively strong correlations between the two, indicating that patients can self-assess their 
disease severity accurately.  
 
All studies included in this review used cross-sectional methods to assess QoL in relation to disease 
severity. Results using this methodology should be interpreted with caution as it’s impossible to 
determine cause and effect. Future studies should utilise prospective designs and collect more 
longitudinal data to strengthen predictive power of psychological and clinical variables of QoL.  AD is 
generally better during the summer and worse in winter58. Only one study specified the season.  
 
Although the quality appraisal for the studies showed that the majority had good to excellent ratings, 
many suffered from methodological weaknesses, such as the use of small sample sizes, or the use of 
non-validated measures. Other issues included absence of statistical testing and incomplete 
presentation of QoL data such as descriptive statistics. In addition, some studies used dermatology 
specific questionnaires to determine QoL in healthy controls.   
 
Conclusions and directions for future research  
This study is the first systematic review and meta-analysis conducted on adults and demonstrates 
that AD influences all aspects of the lives of adult sufferers. Results support findings from previous 
research on similar skin conditions50,60 and in children7,8,47.  The present review points to several 
areas for future research. In the present review, overall scores were difficult to interpret because of 
the variability of scores and the absence of formal reference values or norm scores, or the absence of 
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formal comparisons with population norms. More research with validated psychometric scales is 
needed to generate a consistent body of knowledge of overall QoL of patients with AD. Furthermore, 
application of both generic and disease- or dermatology-specific quality-of-life questionnaire which 
cover the full range of quality-of-life issues are needed. 
 
Second, data on the relationship between specific AD characteristics and QoL suggest that itch, sleep 
disturbances, and exacerbations in facial and genital body areas34 could be relevant predictors of 
quality of life, as reported by a few studies in this review,13,34,45. A deeper insight into these 
relationships is important because of consequences for disease-severity measurement in quality-of-
life research; indeed, a more qualitative approach would help uncover some of these issues. 
 
Researchers in dermatology are encouraged to utilise validated and clinically relevant QoL measures 
for patients that provide accurate measurement of quality of life and allow for subsequent comparison 
of results across studies. Factors such as sleep disturbances and pruritus should be included when 
determining QoL and future studies should also further explore gender differences in QoL in adults 
with AD; only a few studies in this review considered these factors. Longitudinal study designs are 
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Table 1. Study characteristics 
Authors Country N Participants Measures used  Outcomes measured Outcomes measured 








































































































































































































































































































































































































































































































































































































































Table 2 Questionnaires used by studies reporting correlations or mean differences across groups for 


















  ****     
Baron, Morris, Dye, Fielding, & Goulden (2006)  **      ** 
Beikert, Langenbruch, Radtke, Kornek, Purwins, & 
Augustin (2014) 
***    ***   
Chen, Wu, Li, Ko, Yu, & Chen et al, (2012)    ***  ***   
Chrostowska‐Plak, Reich, & Szepietowski (2012)  **       
Coghi, Bortoletto, Sampaio, Junior, & Aoki (2007)  *      * 
Eckert, Gupta,  Amand, Gadkari., & Mahajan 
(2016) 
  ****  ****   
Finlay (1996)      ***   
Fivenson, Arnold, Kaniecki, Cohen, Frech, & Finlay 
(2002) 
***  ***     
Grob, Revuz, Ortonne, Auqueir, & Lorette (2005)      ****   
Haeck, Berge, Velsen, Bruin‐Weller, Bruijnzeel‐
Koomen, & Knol (2011) 
**       
Higaki, Kawamoto, Kamo, Ueda, Arikawa, & 
Kawashima (2004) 
****      **** 
Holm, Agner, Clausen, & Thomsen, (2016)  **       
Holm, Esmann, & Jemec (2004)  ***      *** 
Holm, Wulf, Stegmann, & Jemec (2006)  ***  **    •• 
Kiebert, Sorensen, Revicki, Fagan, Doyle, Cohen & 
Fivenson (2002) 
***  ***     
Kim, Li, Seo, Jo, Yim, Kim, et al (2012)  **       
Kong, Han, Lee, & Son (2016)  **       
Kwak & Kim (2017)    ****     
Lee, Lee, Lee, Lee, Lee, & Park. (2018)    ****     
Linnet & Jemec (1999)  **  **     
Lundberg, Johannesson, Silverdahl, Hermansson 
& Lindberg (2000) 
***  ***  ***   
Maksimovic, Jankovic, Marinkovic, Sekulovic, 
Zivkivic, & Spiric (2012) 
*      * 
Mikołajczyk, Rzepa, Król, & Żaba, (2017).        *** 
Misery, Finlay, Martin, Bousetta, Nguyen, Myon, 
et al (2007) 
        ** 
Misery, Seneschal, Ezzedine, Heas,  Merhand, 
Reguiai, & Taieb, (2017) 
      ** 
Mozaffari, Pourpak, Pourseyed, Farhoodi, 
Aghasmohammadi, & Movahadi et al (2007) 
***  ***     
Noh, Kim, Park, Hann, & Oh (2013)    *  *   
Sanchez‐Perez, Dauden‐Tello, Mora, & Surinyac 
(2012) 
***      *** 
Silverberg,  Gelfand, Margolis, Boguniewicz, 
Fonacier, Grayson, & Fuxench. (2018) 
**    **   
Torrelo, Ortiz, Alomar,Ros, Pedrosa, & Cuervo 
(2013) 
      *** 













































CPD questions  







2. How does disease severity relate to quality of life in patients with atopic dermatitis? 
a) There is no relationship between disease severity and quality of life in patients with 
atopic dermatitis 
b) There is a significant positive relationship between disease severity and quality of life 
such that quality of life gets worse as severity increases in patients with atopic 
dermatitis 
c) There is a significant negative relationship between disease severity and quality of life 
such that quality of life improves as severity increases in patients with atopic 
dermatitis 
d) It is unclear from the literature if there is a relationship between disease severity and 
quality of life in patients with atopic dermatitis 
e) There is a positive relationship between disease severity and quality of life, but it is 
not significant 
 
3. What does the DLQI stand for in Dermatology?  
a) Dermatological Life Quality Index 
b) Dermatology Life Quality Index 
c) Dermatology Life Quality Indicator 
d) Dermatological Life Quality Indicator 
e) Dermatology Life Quality Indices  
 
4. Why might the Short-form Survey (SF-36) not be useful to use with patients with atopic 
dermatitis?  
a) It contains questions that may be too sensitive for patients with atopic dermatitis 
b) It contains questions that may not be relevant to patients with atopic dermatitis  
c) It is not a good measure of quality of life 
d) It is not a validated psychometric scale 
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e) It takes too long to complete 
 
5. What aspect of quality of life has been found to be most affected in atopic dermatitis 
patients?  
a) Personal relationships  
b) Symptoms and feelings surrounding atopic dermatitis 
c) Social relationships  
d) Daily activity  
e) Leisure activities  
 
6) Approximately 20% of adults with AD were first diagnosed with the condition after the 
age of 18:  
 
a) True 
b) False  
 




b) False  
 





9) when using the SF-36, better physical quality of life was reported in patients compared to 
mental quality of life:  
 
a) True 





10) Most patients with atopic dermatitis who take part in studies assessing their quality of life 







Fig 1: Diagram of article flow during literature search and article screening according to the Preferred 








Papers retained for screening by title 
n = 6951 
Papers excluded after screening titles 
n = 6821 
Papers retained for abstract screening 
n = 130 Papers excluded after screening 
abstracts (with reasons) 
 
Non-Atopic Dermatitis- 26 
Children and adults grouped into one analysis -
19 
Non-English- 1 
Not looking at quality of life -27 
Not assessing patient directly- 11 
  n= 84 
Full text papers accessed for detailed 
evaluation 
n = 46 
Conference abstracts and non-English   
n = 6 
  
Studies included in qualitative 
synthesis  
n = 32 
Papers excluded after reading full text 
(with reasons) 
Children and adults grouped together = 2 
Non-atopic dermatitis = 1 
Not measuring QoL directly = 2 
Grouping AD with other skin conditions = 3 
 
 
n = 8 
Full text papers read 
n = 40 
Studies included in quantitative 
synthesis (meta-analysis) 
n = 7 
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Fig 2: Meta‐analysis of studies measuring QoL using DLQI in relation to SCORAD. 
 
 
